%PDF-1.4
%
47 0 obj
<>
endobj
44 0 obj
<>
endobj
115 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-07-21T15:21:59Z
2024-03-28T23:57:54-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T23:57:54-07:00
application/pdf
Heather
2003-155.aug.supl 67
uuid:9793cbd7-1dd1-11b2-0a00-ab0827bd7200
uuid:9793cbd9-1dd1-11b2-0a00-880000000000
endstream
endobj
33 0 obj
<>
endobj
34 0 obj
<>
endobj
48 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 23 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
131 0 obj
[135 0 R]
endobj
132 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.09151 Tw 10 0 0 10 66 713.1616 Tm
[(T)69.9 (o enhance and make more uniform the control of RA,)]TJ
-0.02679 Tw -1.2 -1.2 Td
(attempts are being made in the UK to devise measurable and)Tj
0.0101 Tw 0 -1.2 TD
(minimum clinical standards that have the full support of the)Tj
0.002 Tc 0.37289 Tw T*
(Royal Colleges, General Medical Council, and central)Tj
-0.00011 Tc 0.02499 Tw T*
(government. Such standards might include:)Tj
0.06 Tw T*
(1. Minimum time of access to specialist services following)Tj
0.02499 Tw T*
(diagnosis of RA)Tj
0.03931 Tw T*
(2. Defined standards of monitoring for those taking disease)Tj
0.02499 Tw T*
(modifying drugs)Tj
0.06911 Tw T*
[(3. )54.8 (A)73.9 (vailability of multidisciplinary services, laboratory and)]TJ
0.02499 Tw T*
(imaging diagnostic facilities, and in-patient beds)Tj
0.009 Tw T*
(4. Optimum number of rheumatologists per defined popula-)Tj
0 Tw T*
(tion)Tj
0.02499 Tw T*
(5. Referral rates for major joint replacements.)Tj
/T1_1 1 Tf
0 Tw 0 -2.4 TD
[(SUMMAR)34.8 (Y)]TJ
/T1_0 1 Tf
0.0845 Tw 0 -1.2 TD
[(The principles of RA)-279.7 (control rely to a considerable degree)]TJ
0.041 Tw T*
(on a successful alliance among governments, other funding)Tj
0.0186 Tw T*
(agencies such as insurance companies, on patients and their)Tj
0.0937 Tw T*
(advocates, and on all professionals involved in the care of)Tj
-0.02431 Tw T*
[(those with RA. )17.8 (The following \(see also )17.8 (T)69.9 (able 2\) summarizes)]TJ
0.0643 Tw T*
[(those principles: the role of the )17.7 (W)79.9 (orld Health Or)17.7 (ganization)]TJ
0.1606 Tw T*
(cannot be overestimated: this is exemplified by the Bone)Tj
0.3557 Tw T*
(and Joint Decade meeting and by our host the Japan)Tj
0.3382 Tw T*
[(Rheumatism Foundation. )17.7 (The exchange of international)]TJ
0.09669 Tw T*
(ideas and experiences at this and other such meetings will)Tj
0.02859 Tw T*
[(enable us to deliver better care for those with RA)-223.9 (and bring)]TJ
0.1483 Tw T*
[(about more ef)17.7 (fective management, particularly in patients)]TJ
0.02499 Tw T*
(with severe disease.)Tj
/T1_1 1 Tf
0 Tw 26.4 33.6 Td
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 325 703.1616 Tm
[(1.)-875.1 (Short CL, Bauer )17.7 (W)91.8 (,)-0.1 ( Reynolds )17.7 (WE. Rheumatoid arthritis: a )]TJ
1.675 -1.25 Td
(definition of the disease and a clinical description based on a )Tj
0 -1.25 TD
(numerological study of 293 patients and controls. Cambridge, MA:)Tj
T*
(Harvard University Press; 1957.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Sokka )17.7 (T)74 (, Kautiainen H, Mottonen )17.7 (T)74 (, et al. )17.7 (W)79.9 (ork disability in)]TJ
1.675 -1.25 Td
(rheumatoid arthritis 10 years after diagnosis. J Rheumatol)Tj
0 Tc 0 Tw T*
(1999;26:1681-5.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (W)79.9 (olfe F)79.7 (, Hawley D. )17.7 (The long-term outcome of rheumatoid arthritis.)]TJ
1.675 -1.25 Td
(Arthritis Rheum 1998;41:1072-82.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (W)79.9 (olfe F)79.7 (, Mitchell D, Sibley J, et al. )17.7 (The mortality of rheumatoid)]TJ
1.675 -1.25 Td
[(arthritis. )54.8 (Arthritis Rheum 1994;37:481-94.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (McIntosh E. )17.7 (The cost of rheumatoid arthritis. Br J Rheumatol)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
(1996;35:781-90.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(6.)-875.1 (Jonsson B, Rehnber)17.7 (g C, Bor)17.7 (gquist L, Larsson C. Locomotor status)]TJ
1.675 -1.25 Td
[(and costs in destructive RA. )54.8 (Acta Orthop Scand 1992;63:207-12.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Musculoskeletal disorders: Providing for the patient\325)54.8 (s needs. )54.8 (A)]TJ
1.675 -1.25 Td
(basis for planning a rheumatology service. London: British Society)Tj
T*
(for Rheumatology; 1994.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (The teaching of Buddha. Ch. 2; 3:94. 508th revised ed. )17.7 (T)69.9 (okyo:)]TJ
0 Tc 1.675 -1.25 Td
(Bukkyo Dendo Kyokai, Kosaido Printing Co.; 1989.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.675 -1.25 Td
[(Rheumatology )54.8 (Association 1987 revised classification criteria for)]TJ
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Boers M. Rheumatoid arthritis. )17.7 (T)35 (reatment of early disease. Rheum)]TJ
2.175 -1.25 Td
[(Dis Clin North )54.8 (Am 2001;27:405-14.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Dougados M, Combe B, Cantagrel )54.8 (A, et al. Combination therapy in)]TJ
2.1381 -1.25 Td
(early rheumatoid arthritis: a randomised, controlled double-blind 52)Tj
T*
(week clinical trial of sulphasalazine and methotrexate compared)Tj
T*
[(with the single components. )54.8 (Ann Rheum Dis 1999;58:220-5.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (The teaching of Buddha. Ch 1; 1:228. 508th revised ed. )17.7 (T)69.9 (okyo:)]TJ
0 Tc 2.175 -1.25 Td
(Bukkyo Dendo Kyokai, Kosaido Printing Co.; 1989.)Tj
ET
0 0 0 0 k
420 777 137 -27 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
0.2162 Tw 8 0 0 8 55 330.5293 Tm
[(T)91.9 (able 2. )]TJ
/T1_0 1 Tf
-0.00011 Tc 0.21629 Tw 4.3347 0 Td
(Principles of a joint disease control program for rheumatoid)Tj
0 Tw -4.3347 -1.25 Td
[(arthritis\321summary)64.9 (.)]TJ
0.02499 Tw 0 -2.5 TD
[(Early diagnosis)-2782.5 (Access to specialist services )]TJ
0 -1.25 TD
(Early intervention)Tj
T*
(Reduce morbidity/mortality)Tj
T*
(Improve quality of life)Tj
T*
[(W)79.9 (ork closely with patient or)17.7 (ganizations)]TJ
T*
(Ensure minimum standard of general education)Tj
T*
(Multidisciplinary approach)Tj
T*
(Encourage multinational research)Tj
T*
(Share ideas\321Bone and Joint Decade)Tj
T*
[(Raise \322profile\323 of RA)-220.2 (among professions, public, politicians)]TJ
T*
(Acknowledge but do not accept current limitations and resources)Tj
-0.00751 Tw T*
[(Encourage international co-operation and uniform standards through )17.8 (WHO )]TJ
/T1_3 1 Tf
0 Tc 0 Tw 8.5 0 0 17 117 293.7611 Tm
(})Tj
ET
0 0 0 1 K
0.5 w
54 313.4 m
296 313.4 l
55 179.4 m
294 179.4 l
S
0 0 0 0 k
408 770 150 -25 re
f*
1 w
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Palferman: RA)-257.3 (contr)36.8 (ol)]TJ
0 Tc 0 Tw 61.9375 -0.0313 Td
(13)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
27 0 obj
<>stream
8;Z\7MfQ]h#ikr7OPa2F)aQS!'26%+cJ#%;R3Nrl11T1npg9[ER(oh&OfiqVip6,j
6fd*I:PKW12\r$$*nQrW?[L3db""(9e/i/t^9=jhW;g,951_+^EK?_gp7'?83[g;93;3!=nC*=(W)Rk.'Z_^P6j>
a)7-H?A7Fto#P1!A3G^ZO$tmcLQ]$+7+r;pSdmp-_!(Q51\e'A4TQuT[F0+
2E!IFR#PMt4%bT^`o'C8IXC;An1t&;[H6f~>
endstream
endobj
31 0 obj
[/Indexed/DeviceRGB 255 30 0 R]
endobj
30 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
60 0 obj
<>
endobj
10 0 obj
<>
endobj
56 0 obj
<>
endobj
12 0 obj
<>
endobj
86 0 obj
<>
endobj
121 0 obj
<>
endobj
17 0 obj
<>
endobj
18 0 obj
<>stream
Hbd`ab`ddtqvH)K-LN f!C,q
1032r[n``g``_PYQ`hia"%4PpLOJU,.I-VK/*/J,IMSPpQ PPZZTR!X!Q(1%57([!?M'3/ U]!1/E?H!483%3(3Ybwęǿ?]wf"݁nĮ9l릥cy2m~G'{yoV2o[xsl+ݞںC;*L;kwYlM.sJ<s ؓ
endstream
endobj
50 0 obj
<>
endobj
79 0 obj
<>stream
HtU PiNPqLrDtYeDYp!r 7g 9S[aUGYw]qy٣ݭҭ_{_}qq|&/ۖHeXiĄ+ع8
;`g{joĞ賷eEz$IWh<#9b$;ݗ{lkҨhxqįW ֮{E%]J"SErEJ&{Ɗ*
RHo;K0J))bbi\"b)T+0TOo?ùMð`1!"sð-6S cA5_,iKHmm?IVRqT/o xv~v]vO<0}P{}3fϨ!9:sT46v[mHw]m<[ۙ#Fdhҳ-Re,E@5#wzuSS}}S^.WY
spqsؐ5OЬ4Цn+u{mX!'$.yDjoN}KeOk`Y_`dݒV@;g|m2WPPT%+@#1
Ƈ8|?BJk)_o
*!VO݃.-}U$FdAx|?)sM%MwWuG|' Cm=]w2&wؘ(͊TT$3H)CAYi=ԁUNZ*@IɭRhp;Wx¹Ч3tٛwt:S?q]pu`VՓjr$9PBm!P|ևDV)`;T.?#Y-ʪ7ڿ\1umE{HTfP#]&c&? ~ Nad>2,
+T$;؞D-'aJl* aaq7zRG69sOJZ oQqa~+)Pfi67F1NfR;k
7կMFDZBosAhyÅי
3RB|Gi;{R{o]8Y_1ԸW8B
X~ߌ #
^)lŰEtrש_YB]hc|}5,\_nB2 ijO|\k f}Xh dJ*$C,DӨC.yTn.fy-4{z2*78|6c2Jo(dPWs`Gh?rϒ(c\|ve<Zf^/.?*d*<:SgO"H49Тh&,/'pK8 AJ0r[V#}B ]wqvnnju?4WO[}nw %[cB j"+VcpNn70UF++vJU